NCT00150384已完成4 期
Clinical Utility Of Caduet In Simultaneously Achieving Blood Pressure And Lipid Endpoints In A Specific Patient Population (CAPABLE)
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.107 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2004年7月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 500
- 试验地点
- 107
- 主要终点
- To evaluate the efficacy of Caduet therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III)
研究概览
简要总结
The purpose is to demonstrate the utility of Caduet (amlodipine/atorvastatin) in the African American population
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •African American men and women with concurrent hypertension and dyslipidemia that is either treated or untreated
- •Subjects must satisfy the blood pressure and LDL-C inclusion criteria for their respective Cardiovascular Risk group determined at screening
排除标准
- •Subjects currently being treated with concomitant amlodipine and atorvastatin therapy, including Caduet
- •Subjects with blood pressure at goal
结局指标
主要结局
To evaluate the efficacy of Caduet therapy by assessing the percentage of intent-to-treat subjects achieving both BP and lipid treatment goals (JNC VII and NCEP ATP III)
次要结局
- To assess the percentage of subjects achieving treatment goals(JNC VII and NCEP) stratified by the final BP and lipid therapy doses, respectively, the change from baseline in lipid profile, SBP and DBP
研究者
研究点 (107)
Loading locations...
相似试验
已完成
不适用
Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)HypertensionHypercholesterolemiaAngina PectorisFamilial HypercholesterolemiaNCT01107743Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1,291
已完成
3 期
Amlodipine/Atorvastatin Combination to Reduce the Health Risk of High Blood Pressure and High Cholesterol LevelsHypertensionHyperlipidemiaNCT00143234Pfizer's Upjohn has merged with Mylan to form Viatris Inc.1,825
Unknown
2 期
A Dose Selection Trial of CKD-330 in Patients With Essential HypertensionEssential HypertensionNCT02206165Chong Kun Dang Pharmaceutical456
已完成
4 期
Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum MalariaMalariaNCT00425763Centers for Disease Control and Prevention110
已完成
3 期
Efficacy/Safety of Valsartan Plus Amlodipine and Valsartan Alone in Patients With HypertensionHypertensionNCT00413413Novartis Pharmaceuticals1,134